Telitacicept for children with myasthenia gravis affecting the eyes
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial is testing a new medication called telitacicept to see if it can help children with eye muscle weakness from myasthenia gravis. It aims to find a more effective and safe treatment for this condition, which can affect vision and daily activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be under 18 years old.
- Diagnosis of ocular myasthenia gravis (weakness of eye muscles) confirmed by a doctor.
- Currently on a stable dose of standard treatments like pyridostigmine (Mestinon) or steroids (e.g., prednisone).
- No active infections such as hepatitis B, and no severe liver or kidney problems.
- Not within 3 months after thymus gland removal surgery, and no history of allergy to biological drugs.
- No other cancer (except thymoma) and no participation in other clinical trials recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
This trial tests a new drug called telitacicept combined with low-dose steroids for people with myasthenia gravis that hasn't improved with standard treatments. It aims to reduce muscle weakness and improve daily function.
This trial tests an investigational drug called telitacicept for people with inflammatory myopathy (muscle inflammation). It may help reduce muscle weakness and other symptoms when standard treatments haven't worked well enough.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This study tests a medicine called telitacicept for children with IgA nephropathy or IgA vasculitis nephritis, two kidney diseases that cause protein in the urine. The goal is to see if the medicine can reduce protein loss and help protect the kidneys.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hear when a new Effectiveness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.